General MedicationsSUBCUTANEOUSGeneric
IPLEX
MECASERMIN RINFABATE RECOMBINANT
Standard Dose
36MG/0.6ML
Max Dose
Refer to approved labeling
Primary Use
Review priority: N/A Marketing status: Discontinued
Summary
Approval overview IPLEX is listed in Drugs@FDA under application 021884 (BLA).
Review priority: N/A Marketing status: Discontinued Active ingredient MECASERMIN RINFABATE RECOMBINANT Form and strength INJECTABLE;SUBCUTANEOUS - 36MG/0.6ML Sponsor INSMED Submission history Latest submission status date: 2007-02-27 00:00:00.
Structured Monograph
Clinical summary
Approval overview IPLEX is listed in Drugs@FDA under application 021884 (BLA). Review priority: N/A Marketing status: Discontinued Active ingredient MECASERMIN RINFABATE RECOMBINANT Form and strength INJECTABLE;SUBCUTANEOUS - 36MG/0.6ML Sponsor INSMED Submission history Latest submission status date: 2007-02-27 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: N/A
Interaction Notes
- No interaction notes stored yet.